Hypophosphatemia and Outcomes in ICU: A Systematic Review and Meta-Analysis.

hypophosphatemia intensive care length of stay meta-analysis mortality systematic review

Journal

Journal of intensive care medicine
ISSN: 1525-1489
Titre abrégé: J Intensive Care Med
Pays: United States
ID NLM: 8610344

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 14 8 2020
medline: 19 8 2021
entrez: 14 8 2020
Statut: ppublish

Résumé

Hypophosphatemia is reported in up to 5% of hospitalized patients and ranges from 20% to 80% in critically ill patients. The consequences of hypophosphatemia for critically ill patients remain controversial. We evaluated the effect of hypophosphatemia on mortality and length of stay in intensive care unit (ICU) patients. MEDLINE, EMBASE, Cochrane Library (Reviews and Trials), and PubMed were searched for articles in English. The primary outcome was mortality and secondary outcome was length of stay. The quality of evidence was graded using a modified Newcastle-Ottawa Scale. Our search yielded 828 articles and ultimately included 12 studies with 7626 participants in the analysis. Hypophosphatemia was associated with increased hospital length of stay (2.19 days [95% CI, 1.74-2.64]) and ICU length of stay (2.22 days [95% CI, 1.00-3.44]) but not mortality (risk ratio: 1.13 [95% CI, 0.98-1.31]; Hypophosphatemia in ICU was associated with increased hospital and ICU length of stay but not all-cause mortality. Hypophosphatemia appears to be a marker of disease severity. Limited number of available studies and varied study designs did not allow for the ascertainment of the effect of severe hypophosphatemia on patient mortality.

Identifiants

pubmed: 32783487
doi: 10.1177/0885066620940274
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1025-1035

Auteurs

Jeremy Cheuk Kin Sin (JCK)

Intensive Care Unit, 60077Redcliffe Hospital, Redcliffe, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Lillian King (L)

Intensive Care Unit, 60077Redcliffe Hospital, Redcliffe, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Emma Ballard (E)

56362QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Stacey Llewellyn (S)

56362QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.

Kevin B Laupland (KB)

550021Department of Intensive Care Services, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Queensland University of Technology, Brisbane, Queensland, Australia.

Alexis Tabah (A)

Intensive Care Unit, 60077Redcliffe Hospital, Redcliffe, Queensland, Australia.
Faculty of Medicine, University of Queensland, Brisbane, Queensland, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH